Connect Biopharma Announces Continued Enrollment in Phase 2 Seabreeze STAT Studies Following Positive Interim Analysis
Key Developments in Asthma and COPD Clinical Programs
Connect Biopharma Holdings Ltd (Nasdaq: CNTB), a clinical-stage biopharmaceutical company developing novel therapies for inflammatory diseases, has announced a significant milestone for its ongoing Phase 2 Seabreeze STAT clinical studies. The independent Data Monitoring Committee (DMC) overseeing the company’s trials for rademikibart in acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) has completed a pre-specified interim analysis and recommended that enrollment continue as planned, with no changes to the sample size.
Details of the Interim Analysis
- The DMC reviewed interim efficacy data, including treatment failure at 28 days, rate of new exacerbations through 28 days, and change from baseline in FEV1, for at least 50 patients per study with a minimum of 28 days’ follow-up.
- No recommendations were made to alter the sample size, indicating that the studies are proceeding as expected.
- The DMC also reviewed safety data and found no safety concerns. There have been no treatment-related serious or severe adverse events, and no patient discontinuations due to adverse events in either study.
CEO’s Statement and Forward Outlook
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma, stated, “Based on the DMC’s review of interim efficacy results from our ongoing Seabreeze STAT asthma and COPD studies, enrollment will continue as planned with no change in sample size. Rademikibart continues to be well tolerated in these studies of patients experiencing acute exacerbations. We continue to believe that rademikibart has the potential to deliver differentiated efficacy and safety in patients with type 2 asthma and COPD experiencing acute exacerbations. We remain on track to report topline results from both Seabreeze STAT studies mid-year (2026).”
Upcoming Catalysts and Potential Share Price Impact
- Topline Data Expected: Connect Biopharma anticipates reporting topline data from both Phase 2 Seabreeze STAT studies (asthma and COPD) in mid-2026. Positive data could serve as a major price-moving catalyst for the company’s shares.
- Regulatory Pathway: Contingent upon positive Phase 2 results, the company plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 program, which would be a critical step toward potential approval and commercialization.
- Licensing and Milestone Payments: The company has granted Simcere Pharmaceutical Co., Ltd. exclusive rights to rademikibart in Greater China. Connect Biopharma is eligible for up to \$110 million in additional milestone payments and tiered royalties up to low double-digit percentages on net sales in Greater China, providing a potential revenue stream that could impact future share price.
About Rademikibart
Rademikibart is a fully human monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα), a shared subunit of the interleukin-4 and interleukin-13 receptors. By blocking IL-4Rα, rademikibart is designed to inhibit the T helper 2 (Th2) inflammatory pathway, which plays a key role in diseases such as atopic dermatitis, asthma, and COPD. The drug is being evaluated for its potential to provide best-in-class efficacy and safety in addressing acute exacerbations in asthma and COPD—areas of significant unmet medical need.
Investor Considerations and Forward-Looking Statements
- Shareholders should note that continued enrollment and positive safety signals at the interim stage are encouraging, but final efficacy and regulatory outcomes remain pending.
- Any positive topline data or regulatory progress could significantly impact the company’s valuation.
- Risks remain, including the possibility that results from ongoing trials may not be replicated in later-stage studies or may not result in regulatory approval.
Contact Information
For further inquiries, investors can contact:
Investor Relations: Alex Lobo, Precision AQ ([email protected]), (212) 698-8802
Media Contact: Ignacio Guerrero-Ros, Ph.D., or David Schull, Russo Partners, LLC ([email protected], [email protected]), (858) 717-2310 or (646) 942-5604
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. The information is based on a company press release and public disclosures as of the date indicated. Clinical trial outcomes are uncertain, and forward-looking statements involve risks and uncertainties. Investors should conduct their own due diligence and consult with professional advisors before making investment decisions.
View Connect Biopharma Holdings Ltd Historical chart here
